Background: Prostate Specifi c Antigen (PSA) has been widely used in the diagnosis and management of patients with prostate cancer. It may be elevated in other prostatic diseases and surgical procedures. PSA exists in two forms, a major bound form (cPSA) and a free form (fPSA). Objectives: The objective of the study was to determine the relationship between serum fPSA levels and histologic fi ndings in biopsy specimens of men with prostatic disease.
P
rostate specifi c antigen (PSA), a "glycoprotein serine protease", was fi rst identifi ed by Wang et al in 1979 1 . It is a widely used serum marker fi rst designed for the early detection and monitoring of patients with prostate cancer (PCa) [2] [3] [4] [5] . However it is evident now that a raised PSA level can also occur in non-malignant conditions like benign prostatic hyperplasia (BPH), infl ammation, diagnostic and surgical procedures. These conditions may mimic cancer and cause confusion in diagnosis especially in PCa detection programs that use PSA as a screening test. Immunoreactive PSA (total PSA [tPSA]) exists in two forms, a major fraction is bound to serum proteins (cPSA) and about 10-30% is free (fPSA). There are reports on relationship between serum tPSA levels and histological fi ndings on prostate biopsies. Free PSA measurements can be used to improve the specifi city of PSA for PCa, especially when tPSA values are between 4.0 and 10.0ng/ml. To the best of our knowledge, the relationship between fPSA and histologic fi ndings have not been determined so far. Hence this study was undertaken to investigate the relationship between serum fPSA values and histologic fi ndings in biopsy specimens of men with prostatic disease.
Materials and methods
This study included 91 patients with prostatic disease planned for surgery who attended the urology clinic of Medicare National Hospital and Research Centre from January 2008 to December 2009. Blood samples were taken before transurethral resection of the prostate (TURP), and at least a week after digital rectal examination to avoid possible errors caused by the release of PSA from the prostate. The serum samples were stored at -20 ºC and were tested for fPSA within 4 days. Free PSA was estimated by sandwich ELISA technique using high affi nity Biotin-Streptavidin system, with analytical sensitivity of 0.05ng/mL (HUMAN, Germany).
The tissue samples collected after TURP were fi xed in 10% formalin. The tissue was prepared routinely, embedded in paraffi n, cut to a thickness of four microns and stained by Hematoxylin-Eosin. The biopsy was studied by a pathologist without the knowledge of the result of serum fPSA value and grouped accordingly. I. Benign prostatic hyperplasia without and with infl ammation, which includes chronic prostatitis, acute prostatitis, chronic active prostatitis. II. Prostatic intraepithelial neoplasia (PIN), which includes, Low-grade PIN (LGPIN) and High-grade PIN (HGPIN). III. Prostate Cancer (PCa), which includes, Low-grade PCa (LGPCa) and High-grade PCa (HGPCa).
Statistical analysis
Data were analysed using the statistical software package SPSS 11.5 for Windows (SPSS). Associations between different diagnostic categories and fPSA were tested with chi square test. Receiver operating characteristic (ROC) curve was generated using SPSS for window. Pvalue <0.05 was considered as statistically signifi cant. Of the 75 benign lesions, 65.33 % were BHP without concurrent infl ammation, while 28%, 2.66% and 4% of them showed chronic, chronic active and acute infl ammation respectively. Most cases of BHP without infl ammation (46.66%) had fPSA below 2.0 ng/mL, while most with acute infl ammation showed fPSA more than 5.0 ng/mL. The association between the diagnosis and fPSA ranges studied was statistically signifi cant (p< 0.001, Table 2 ).
Results

This
The premalignant cases comprising LGPIN and HGPIN and malignant cases comprising LGPCa and HGPCa were separately analysed for fPSA levels. The fPSA values of all seven cases of LGPIN were lower than 5.0 ng/mL while patients of HGPIN and majority of PCa had values higher than 5.0 ng/mL. The association between different diagnostic groups and fPSA ranges was statistically signifi cant (p<0.05, Table 3 ).
As most of the benign cases and all LGPIN showed fPSA values signifi cantly lower (< 5.0 ng/mL) than high grade lesions, ROC analysis was done to fi nd an appropriate cut off fPSA value for differentiating HGPIN and PCa from the former (Fig 2) . The sensitivity and specifi city of 88.8% and 90.24% respectively can be achieved using cut off value of 5.0 ng/mL (Table 4) . The association between the two diagnostic groups using this cut off value was statistically signifi cant (p<0.001, Table 5 ). Odds ratio calculated was 74 (95%CI: 8.174 to 669.938). The clinically applicable reference values of tPSA is from 0 -4.0 ng/mL, but even within the "normal" range of PSA there is also the risk of cancer albeit at a smaller rate of 2%. Intermediate values, i.e., value from 4.0-10.0 ng/mL could be seen in patients with BPH, prostatitis, PIN and PCa [8] [9] . Serum fPSA level ranging from 0.4 to 1.3 is used as reference value in most laboratories. In this study, the fPSA level in patients of BPH ranged from 0.04 -19.82 ng/mL. BPH is a heterogenous disease that is characterized histologically by a variable degree of stromal and epithelial hyperplasia. Thus men with a predominance of epithelial hyperplasia are expected to have greater increases in PSA levels than men with predominant stromal hyperplasia. The variation in PSA levels in BPH can also be explained by the detection of various degrees of infl ammatory changes detected histologically in TURP specimens. Twenty six (34.6%) of our BPH patients had histological prostatitis. Kohner et al reported that 98.1% of BPH had histological prostatitis 10 . Blumfeld et al also reported that lymphocytic prostatitis was present in 95% of TURP specimens 11 . Many reports indicate that the serum PSA level is elevated in patients with clinical acute prostatitis [12] [13] [14] [15] . The results of our study show that fPSA of patients with BPH without infl ammation and patients with chronic infl ammation ranged from normal level to 3.0 ng/mL, while patients with active infl ammation had values more than 3.0 ng/mL. The mechanism through which histological infl ammation within the prostate elevates serum PSA levels remains poorly understood. The epithelial cells surrounding the affected area may be stimulated to produce PSA through unknown substances released in association with the infl ammatory processes 16 . On the other hand, Hasui et al suggested that the abnormal elevation of serum PSA levels is caused by leakage of PSA stored in the epithelial cells into the stromal tissue and blood circulating after epithelial cell death 17 .
In our study LGPIN was seen in 7.69% of the 91 patients. The fPSA levels in these patients were slightly elevated to levels less than 5.0 ng/mL, while the levels were above 5.0 ng/mL in HGPIN. Some studies suggest that PIN causes serum PSA elevation 18 , while other studies dispute this relationship 19, 20 . In our study most of the patients with prostatic carcinoma had serum fPSA levels more than 5.0 ng/mL.
In this study though mean value of fPSA in PCa is statistically different than in the cases of BPH, fPSA in some cases of BPH is as high as 19.8 ng/mL and fPSA in one case of PCa is as low as 1.82 ng/mL. Similar overlap has been witnessed in a number of studies using total PSA values, making selection of an optimum cut off value still controversial. One study has shown that clinical sensitivity of tPSA is 78% at a cut-off value of 4.0 ng/mL. By lowering the cut-off value to 2.8 ng/ mL, sensitivity increases to 92%, whereas specifi city decreases from 33% to 23%. Raising the cut-off value to 8.0 ng/mL improves the specifi city to 90%. 21 In our data, though there is overlap of fPSA values between BPH and PCa, yet it is statistically different. Clinical sensitivity of fPSA to distinguish PCa from BPH is 100% at cut-off value of 1.81 ng/mL. However, at the cut-off value the specifi city remains poor with only 49%. By raising the cut-off value to 12.65 ng/mL, specifi city can improve to 94%, limiting sensitivity to only 60% (Table  4) . ROC analysis of our data suggest that use of cut-off value of 5.0 ng/mL will be optimum for clinical use to differentiate PCa with BPH as, sensitivity of 88.8% and specifi city of 90.2% can be achieved.
There are limitations of this study. Patients with acute retention of urine (which may cause elevation in PSA levels) 22 were not excluded from the study. Histologic correlation was done on TURP specimens and not prostatectomy specimens.
Conclusion
Serum fPSA is elevated marginally in patients with BPH without infl ammation and patients with chronic infl ammation. The higher grade lesions (HGPIN and PCa) are associated with fPSA values more than 5 ng/ ml. Since overlapping high values were also observed in acute prostatitis, we should tend to be more cautious about high-grade lesions that have not yet been diagnosed on TURP and a radical prostatectomy may have to be performed for evaluation.
